Preparation method and application of a CD132 gene-deleted immunodeficiency animal model
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- BIOCYTOGEN JIANGSU CO LTD
- Publication Date
- 2020-03-13
Smart Images

Figure 1 
Figure 2 
Figure 3
Abstract
Description
technical field
[0001] This application belongs to the field of animal genetic engineering and relates to CRISPR / Cas9 technology, in particular to a method for obtaining an animal model of immunodeficiency based on CRISPR / Cas9 gene knockout technology and an sgRNA for specifically targeting the CD132 gene. Background technique
[0002] CRISPR / Cas9 is an emerging technology discovered in recent years that the RNA-guided Cas9 nuclease targets the target gene for editing. In the CRISPR / Cas9 system, crRNA (CRISPR-derived RNA) combines with tracrRNA (trans-activating RNA) to form a double-stranded RNA through the principle of DNA base pairing, and guides the Cas9 protein to cut the double-stranded RNA at the target site of the crRNA-guided DNA sequence. strand DNA. The CRISPR / Cas9 system can realize highly flexible and specific genome editing in eukaryotic cells. It is currently the most popular new-generation genome editing technology in the field of genome editing. At present,...